Citations

Clear

3942 citation(s) found for "To, Van".

Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers.
Overman, Michael J. , Fogelman, David R. , Wolff, Robert A. , Morris, Van K. , Kee, Bryan K. , Dasari, Arvind , Raghav, Kanwal , Shureiqi, Imad , Johnson, Benny , Parseghian, Christine Megerdichian , Eng, Cathy , Garg, Naveen , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 4047-4047

10.1200/jco.2020.38.15_suppl.4047 Get It

4047 Background: BRAFV600E mutations occur in fewer than 10% of all patients (pts) with metastatic colorectal cancer (mCRC) and arise from sessile serrated adenomas. Despite efficacy with targeted therapies against MAPK signaling and with immunotherapies in this population, survival outcomes for pts with BRAFV600E mCRC in general are poor. Characteristics distinguishing pts with BRAFV600E mCRC with favorable versus unfavorable outcomes have not been well annotated. Methods: Records of 188 pts with BRAFV600E mCRC evaluated at MD Anderson Cancer Center between 3/2010-1/2020 were reviewed. Pts with the shortest and longest metastatic survival (N = 25 for each group) were compared. Associations between prognostic group and clinical/pathologic features were measured by odds ratio and for median survival by log-rank testing. Results: Median metastatic survival differed between the 2 BRAFV600E mCRC populations (8.6 vs 84 months, p < .0001). Pts with poor survival more commonly had primary tumors arising from the hepatic flexure/proximal transverse colon (44% vs 16%, p = .04) and more frequent hepatic involvement (75% vs 28%, p = .001). Pts with favorable survival were more likely to develop metachronous metastases (52% vs 16%, p = .01), have fewer distant organ involvement (median 1 vs 2, p = .02), and undergo definitive locoregional therapy to metastatic disease (44% vs 0%, p = .01). Microsatellite instability (36% vs 4%, p = .008) and a history of tobacco use (44% vs 16%, p = .04) were associated with a favorable prognosis. Durable responses to MAPK-targeted therapies (5/25) and immunotherapy (3/25) were noted in the favorable group. Conclusions: Pts with BRAFV600E mCRC can achieve excellent long-term survival which belies conventional context and is driven by locoregional and systemic treatment options alike. Anatomic localization of the primary tumor and prior exposures may highlight environmental influences on tumor biology which account for the clinical heterogeneity of pts with BRAFV600E mCRC.
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
Bustoros, Mark , Sklavenitis‐Pistofidis, Romanos , Park, Jihye , Zhitomirsky, Benny , Salem, Karma Z. , Chavda, Selina J , Boehner, Cody J. , Elagina, Liudmila, Neuse, Carl Jannes , Cha, Justin , Rahmat, Mahshid , Kumar, Shaji , Kastritis, Efstathis, Laubach, Jacob P. , Casneuf, Tineke, Richardson, Paul G. , Munshi, Nikhil C. , Trippa, Lorenzo , Bergsagel, P. Leif , Manier, Salomon , Ghobrial, Irene M. , Bergsagel, P. Leif , Ghobrial, Irene M , Sklavenitis-Pistofidis, Romanos , Redd, Robert , Dunford, Andrew , Tai, Yu‐Tzu , Anand, Shankara K. , Mouhieddine, Tarek H. , Taylor-Weiner, Amaro N , Van Allen, Eliezer M , Leshchiner, Ignaty , Morgan, Elizabeth A. , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Aguet, François , Stewart, Chip , Dimopoulos, Meletios Α. , Yong, Kwee , Getz, Gad

Mayo Clinic

Journal of Clinical Oncology | May 22, 2020 | Volume: 38 | Issue: 21 | Pages: 2380-2389

10.1200/jco.20.00437 | PMID 32442065 Get It

PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. METHODS We used next-generation sequencing to study 214 patients with SMM. We performed whole-exome sequencing on 166 tumors, including 5 with serial samples, and deep targeted sequencing on 48 tumors. RESULTS We observed that most of the genetic alterations necessary for progression have already been acquired by the diagnosis of SMM. Particularly, we found that alterations of the mitogen-activated protein kinase pathway ( KRAS and NRAS single nucleotide variants [SNVs]), the DNA repair pathway (deletion 17p, TP53, and ATM SNVs), and MYC (translocations or copy number variations) were all independent risk factors of progression after accounting for clinical risk staging. We validated these findings in an external SMM cohort by showing that patients who have any of these three features have a higher risk of progressing to MM. Moreover, APOBEC associated mutations were enriched in patients who progressed and were associated with a shorter time to progression in our cohort. CONCLUSION SMM is a genetically mature entity whereby most driver genetic alterations have already occurred, which suggests the existence of a right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM. We identified and externally validated genomic predictors of progression that could distinguish patients at high risk of progression to MM and, thus, improve on the precision of current clinical models.
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia
Zhou, Yalu, Han, Cuijuan , Wang, Eric , Lorch, Adam H., Serafin, Valentina , Cho, Byoung-Kyu , Gutierrez-Diaz, Blanca T. , Calvo, Julien , Fang, Celestia, Khodadadi‐Jamayran, Alireza , Tabaglio, Tommaso , Marier, Christian, Kuchmiy, Anna , Sun, Limin , Yacu, George, Filip, Szymon K. , Jin, Qi , Takahashi, Yoh-hei, Amici, David R. , Rendleman, Emily J. , Rawat, Radhika , Paganin, Maddalena , Kandela, Irawati , Politanska, Yuliya , Palhais, Bruno , Vlierberghe, Pieter Van , Taghon, Tom , Aifantis, Iannis , Goo, Young Ah , Guccione, Ernesto , Heguy, Adriana , Tsirigos, Aristotelis , Wee, Keng Boon , Mishra, Rama K. , Pflumio, Françoise , Accordi, Benedetta , Ntziachristos, Panagiotis , Jin, Qi , Taghon, Tom , Goo, Young Ah , Tsirigos, Aristotelis , Basso, Giuseppe , Khodadadi-Jamayran, Alireza , Van Vlierberghe, Pieter , Gutierrez Diaz, Blanca , Cho, Byoung-Kyu , Han, Cuijuan , Serafin, Valentina , Jin, Qi , Takahashi, Yoh-Hei, Bresolin, Silvia , Zhang, Cheng , Li, Hu , Abdala‐Valencia, Hiam , Mendillo, Marc L. , Zhu, Ping, Basso, Giuseppe , Jin, Qi

Mayo Clinic

Cancer Discovery | May 22, 2020 | Volume: 10 | Issue: 9 | Pages: 1388-1409

10.1158/2159-8290.cd-19-1436 | PMID 32444465 Get It

Abstract Splicing alterations are common in diseases such as cancer, where mutations in splicing factor genes are frequently responsible for aberrant splicing. Here we present an alternative mechanism for splicing regulation in T-cell acute lymphoblastic leukemia (T-ALL) that involves posttranslational stabilization of the splicing machinery via deubiquitination. We demonstrate there are extensive exon skipping changes in disease, affecting proteasomal subunits, cell-cycle regulators, and the RNA machinery. We present that the serine/arginine-rich splicing factors (SRSF), controlling exon skipping, are critical for leukemia cell survival. The ubiquitin-specific peptidase 7 (USP7) regulates SRSF6 protein levels via active deubiquitination, and USP7 inhibition alters the exon skipping pattern and blocks T-ALL growth. The splicing inhibitor H3B-8800 affects splicing of proteasomal transcripts and proteasome activity and acts synergistically with proteasome inhibitors in inhibiting T-ALL growth. Our study provides the proof-of-principle for regulation of splicing factors via deubiquitination and suggests new therapeutic modalities in T-ALL. Significance: Our study provides a new proof-of-principle for posttranslational regulation of splicing factors independently of mutations in aggressive T-cell leukemia. It further suggests a new drug combination of splicing and proteasomal inhibitors, a concept that might apply to other diseases with or without mutations affecting the splicing machinery. This article is highlighted in the In This Issue feature, p. 1241
Polysaccharide from angelica sinensis attenuates SNP-Induced Apoptosis in osteoarthritis Chondrocytes by Inducing Autophagy via ERK1/2 Pathway
Zhuang, Chao, Li, Chenkai , Wang, Liangliang , Wang, Yuji , Xu, Chao , Ni, Su , Zhao, Gongyin , Jiang, Shijie , Zhu, Ruixia, Wijnen, André J. van

Mayo Clinic

No container title available | May 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-29285/v1 Get It

Abstract Objective Chondrocyte apoptosis plays a vital role in osteoarthritis (OA) progression. Angelica sinensis polysaccharide (ASP), a traditional Chinese medicine, possesses anti-inflammatory and anti-apoptotic properties in chondrocytes. This study aimed to determine the protective role of ASP on sodium nitroprusside (SNP)-induced chondrocyte apoptosis, and explore the underlying mechanism. Method Human primary chondrocytes isolated from articular cartilage of OA patients were treated with SNP alone or in combination with different dose of ASP. Cell viability and apoptosis were assessed, and apoptosis-related proteins including Bcl-2 and Bax were detected. Autophagy levels were evaluated by light chain 3 (LC3)-II immunofluorescence staining, mRFP-GFP-LC3 fluorescence localisation and western blot (LC3II, p62, Beclin-1, Atg5). Meanwhile,activation of ERK 1/2 pathway was determined by western blot. The autophagy inhibitors 3-Methyladenine (3-MA), chloroquine (CQ) and a specific inhibitor of ERK1/2, SCH772984, were used respectively to confirm the autophagic effect of ASP. Results The results showed that SNP-induced chondrocyte apoptosis was significantly rescued by ASP, whereas ASP alone promoted chondrocytes proliferation. The anti-apoptotic effect of ASP was related to the enhanced autophagy and depended on the activation of ERK1/2 pathway.Conclusion ASP markedly rescued SNP-induced chondrocyte apoptosis by activating ERK1/2-dependent autophagy in chondrocytes, and it made ASP a potential therapeutic supplementation for OA treatment.
Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk
Zhu, Jingjing , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L. , Du, Mengmeng , Goodman, Phyllis J. , Li, Donghui , Bracci, Paige M. , Gallinger, Steven , Arslan, Alan A. , Scélo, Ghislaine , Visvanathan, Kala , Haiman, Christopher A. , Petersen, Gloria M. , Wu, Lang , Shu, Xiao-Ou , Bao, Jiandong , Milne, Roger L , Malats, Nuria , Duell, Eric J , Li, Donghui , Katzke, Verena , Van Den Eeden, Stephen K , Arslan, Alan A , Canzian, Federico , Yu, Herbert , Klein, Alison P , Visvanathan, Kala , Guo, Xingyi , Liu, Duo, Giles, Graham G. , Wu, Chong , White, Emily , Risch, Harvey A. , Malats, Núria , Duell, Eric J. , Neale, Rachel Ε. , Canzian, Federico , Kooperberg, Charles , Freeman, Laura E. Beane , Marchand, Loı̈c Le , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Cai, Qiuyin , Long, Jirong , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 21, 2020 | Volume: 29 | Issue: 7 | Pages: 1501-1508

10.1158/1055-9965.epi-20-0091 | PMID 32439797 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with few known risk factors and biomarkers. Several blood protein biomarkers have been linked to PDAC in previous studies, but these studies have assessed only a limited number of biomarkers, usually in small samples. In this study, we evaluated associations of circulating protein levels and PDAC risk using genetic instruments. Methods: To identify novel circulating protein biomarkers of PDAC, we studied 8,280 cases and 6,728 controls of European descent from the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium, using genetic instruments of protein quantitative trait loci. Results: We observed associations between predicted concentrations of 38 proteins and PDAC risk at an FDR of &lt; 0.05, including 23 of those proteins that showed an association even after Bonferroni correction. These include the protein encoded by ABO, which has been implicated as a potential target gene of PDAC risk variant. Eight of the identified proteins (LMA2L, TM11D, IP-10, ADH1B, STOM, TENC1, DOCK9, and CRBB2) were associated with PDAC risk after adjusting for previously reported PDAC risk variants (OR ranged from 0.79 to 1.52). Pathway enrichment analysis showed that the encoding genes for implicated proteins were significantly enriched in cancer-related pathways, such as STAT3 and IL15 production. Conclusions: We identified 38 candidates of protein biomarkers for PDAC risk. Impact: This study identifies novel protein biomarker candidates for PDAC, which if validated by additional studies, may contribute to the etiologic understanding of PDAC development.
Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome
Lahrouchi, Najim , Crotti, Lia , Mizusawa, Yuka , Postema, Pieter G. , Beekman, Leander , Walsh, Roddy , Hasegawa, Kanae , Barc, Julien , Ernsting, Marko, Turkowski, Kari L. , Mazzanti, Andrea , Beckmann, Britt M., Diamant, Ulla‐Britt , Kucho, Yu, Robyns, Tomas , Winbo, Annika , Jabbari, Reza , Lubitz, Steven A., Steinfurt, Johannes , Rudic, Boris , Shoemaker, Moore B., Weeke, Peter , Davies, Brianna , Andorin, Antoine , Hofman, Nynke , Pedrazzini, Matteo , Tester, David J. , Bos, J. Martijn , Platonov, Pyotr G. , Stallmeyer, Birgit, Zumhagen, Sven, Nannenberg, Eline A., Veldink, Jan H., Berg, Leonard H. van den, Al‐Chalabi, Ammar , Shaw, Christopher E. , Shaw, Pamela J. , Morrison, Karen , Müller‐Nurasyid, Martina , Cusi, Daniele , Lathrop, Mark , Munter, Markus, Aung, Tin , Ozaki, Mineo , Lichtner, Peter , Tintelen, J. Peter van , Hoedemaekers, Yvonne M., Napolitano, Carlo , Gourraud, Jean‐Baptiste , Makiyama, Takeru , Ohno, Seiko , Itoh, Hideki , Roden, Dan M. , Saenen, Johan , Borggrefe, Martin, Odening, Katja E. , Ellinor, Patrick T., Tfelt‐Hansen, Jacob , Skinner, Jonathan R. , Berg, Maarten P. van den , Makita, Naomasa , Breckpot, Jeroen , Yoshinaga, Masao , Behr, Elijah R. , Rydberg, Annika , Aiba, Takeshi , Priori, Silvia G. , Newton‐Cheh, Christopher , Schulze‐Bahr, Eric , Horie, Minoru , Wilde, Arthur A.M. , Tanck, Michael W.T. , Bezzina, Connie R. , Lubitz, Steven A. , Crotti, Lia , Makita, Naomasa , Horie, Minoru , Behr, Elijah Raphael , van Tintelen, J Peter , Odening, Katja E , Bos, Johan M , Tanck, Michael , Barc, Julien , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Lubitz, Steven A , Al-Chalabi, Ammar , Bezzina, Connie R , Gourraud, Jean-Baptiste , Mazzanti, Andrea , Postema, Pieter G , Priori, Silvia , Walsh, Roddy , Tadros, Rafik , Beckmann, Britt-Maria, Shimamoto, Keiko , Wijeyeratne, Yanushi D. , Ishikawa, Taisuke , Arbelo, Elena , Christiansen, Michael , Loeys, Bart , Pfeiffer, Ryan D. , Dagradi, Federica , Sarquella-Brugada, Georgia , Campuzano, Óscar , Berg, Leonard H. van den , Andersen, Peter Munch , Barlassina, Cristina , Galán, Pilar , Werge, Thomas Mears , Ribasés, Marta , Khor, Chiea Chuen , Meitinger, Thomas , Denjoy, Isabelle , Leenhardt, Antoine , Shimizu, Wataru , Schott, Jean‐Jacques , Ohno, Seiko , Krahn, Andrew D. , Antzelevitch, Charles , Roden, Dan M. , Ellinor, Patrick T. , Olesen, Morten S. , Brugada, Josép , Brugada, Ramón , Aiba, Takeshi , Kääb, Stefan , Guicheney, Pascale , Tan, Hanno L. , Ackerman, Michael , Schwartz, Peter J. , Probst, Vincent

Mayo Clinic

Circulation | May 20, 2020 | Volume: 142 | Issue: 4 | Pages: 324-338

10.1161/circulationaha.120.045956 | PMID 32429735 Get It

Background: Long QT syndrome (LQTS) is a rare genetic disorder and a major preventable cause of sudden cardiac death in the young. A causal rare genetic variant with large effect size is identified in up to 80% of probands (genotype positive) and cascade family screening shows incomplete penetrance of genetic variants. Furthermore, a proportion of cases meeting diagnostic criteria for LQTS remain genetically elusive despite genetic testing of established genes (genotype negative). These observations raise the possibility that common genetic variants with small effect size contribute to the clinical picture of LQTS. This study aimed to characterize and quantify the contribution of common genetic variation to LQTS disease susceptibility. Methods: We conducted genome-wide association studies followed by transethnic meta-analysis in 1656 unrelated patients with LQTS of European or Japanese ancestry and 9890 controls to identify susceptibility single nucleotide polymorphisms. We estimated the common variant heritability of LQTS and tested the genetic correlation between LQTS susceptibility and other cardiac traits. Furthermore, we tested the aggregate effect of the 68 single nucleotide polymorphisms previously associated with the QT-interval in the general population using a polygenic risk score. Results: Genome-wide association analysis identified 3 loci associated with LQTS at genome-wide statistical significance ( P <5×10 −8 ) near NOS1AP , KCNQ1 , and KLF12 , and 1 missense variant in KCNE1 (p.Asp85Asn) at the suggestive threshold ( P <10 −6 ). Heritability analyses showed that ≈15% of variance in overall LQTS susceptibility was attributable to common genetic variation ( h2SNP 0.148; standard error 0.019). LQTS susceptibility showed a strong genome-wide genetic correlation with the QT-interval in the general population (r g =0.40; P =3.2×10 −3 ). The polygenic risk score comprising common variants previously associated with the QT-interval in the general population was greater in LQTS cases compared with controls ( P <10−13), and it is notable that, among patients with LQTS, this polygenic risk score was greater in patients who were genotype negative compared with those who were genotype positive ( P <0.005). Conclusions: This work establishes an important role for common genetic variation in susceptibility to LQTS. We demonstrate overlap between genetic control of the QT-interval in the general population and genetic factors contributing to LQTS susceptibility. Using polygenic risk score analyses aggregating common genetic variants that modulate the QT-interval in the general population, we provide evidence for a polygenic architecture in genotype negative LQTS.
Age Is Associated With Pain Experience and Opioid Use After Head and Neck Free Flap Reconstruction
Rettig, Eleni M. , Janus, Jeffrey R. , Moore, Eric J. , Glasgow, Amy E. , Marinelli, John P. , Habermann, Elizabeth B. , Abel, Kathryn M. Van , Glasgow, Amy E. , Marinelli, John P , Van Abel, Kathryn M , Habermann, Elizabeth , Glasgow, Amy E , Price, Daniel L.

Mayo Clinic

The Laryngoscope | May 16, 2020 | Volume: 130 | Issue: 8 | Pages: No page available

10.1002/lary.28713 | PMID 32413165 Get It

ObjectivesTo describe pain experience and opioid use after major head and neck reconstructive surgery.Study DesignRetrospective cohort study.MethodsPatients undergoing major head and neck surgery with microvascular free tissue transfer (free flaps) at a tertiary academic center were included. Pain scores (0–10) and demographic and clinical data were ascertained from medical records. Discharge opioid prescriptions and refills obtained within 30 days were recorded. Patient characteristics were compared with pain scores using nonparametric rank‐sum tests and with likelihood of refill using logistic regression models to calculate adjusted odds ratios (aORs) with 95% confidence intervals (CIs).ResultsThe study population comprised 445 patients. Median age was 60 years (interquartile range 50–68). Most patients had cancer (N = 350, 78%). The majority of free flaps were fibula (N = 153, 34%) or radial forearm (N = 159, 36%). Older patients reported significantly lower pain scores, whereas patients with opioid tolerance, anxiety, current smokers, and those undergoing larger volume resections or boney free flaps reported significantly higher pain scores. One‐quarter (N = 115, 26%) of patients obtained opioid refills. Patients aged ≥ 60 years had one‐half the odds of obtaining a refill compared with patients aged < 60 years (adjusted odds ratio [aOR] = 0.52, 95% confidence interval [CI] = 0.33–0.84), whereas surgical defect volume ≥ 100 cm3 (aOR = 1.92, 95% CI = 1.21–3.07) and higher pain score (aOR = 1.19, 95% CI = 1.07–1.32 per 1 point increase) increased the odds of refill.ConclusionContinued opioid use after discharge is common among patients undergoing major head and neck reconstruction, particularly for younger patients and after more extensive surgery. Older patients reported lower pain intensity and were less likely to obtain opioid refills, highlighting the wisdom of judicious opioid use for this vulnerable population.Level of EvidenceIV Laryngoscope, 130: E469–E478, 2020
Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location
Labadie, Julia , Harrison, Tabitha A. , Banbury, Barbara L. , Amtay, Efrat L, Bernd, Sonja, Brenner, Hermann , Campbell, Peter T. , Cao, Yin , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gunter, Marc J. , Hoffmeister, Michael , Moreno, Vı́ctor , Murphy, Neil , Phipps, Amanda I. , Slattery, Martha L. , Thibodeau, Stephen N. , Guelpen, Bethany Van , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Labadie, Julia D , Banbury, Barbara , Campbell, Peter T , Cao, Yin , Chang-Claude, Jenny , English, Dallas R , Gunter, Marc J , Hoffmeister, Michael , Jenkins, Mark A , Milne, Roger L , Moreno, Victor , Ogino, Shuji , Sakoda, Lori C , Sun, Wei , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Murphy, Neil , Buchanan, Daniel D. , Chan, Andrew T. , English, Dallas R. , Giles, Graham G. , Hsu, Li , Jenkins, Mark A. , Lin, Yi , Milne, Roger L. , Sakoda, Lori C. , Southey, Melissa C. , Sun, Wei , Newcomb, Polly A.

Mayo Clinic

JNCI Cancer Spectrum | May 13, 2020 | Volume: 4 | Issue: 5 | Pages: No page available

10.1093/jncics/pkaa042 | PMID 32923935 Get It

AbstractBackgroundPostmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location.MethodsWe pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: adenoma-carcinoma, alternate, serrated), tumor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and 4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for the association of ever vs never HT use with each tumor subtype compared with controls. Models were adjusted for study, age, body mass index, smoking status, and CRC family history. All statistical tests were 2-sided.ResultsAmong postmenopausal women, ever HT use was associated with a 38% reduction in overall CRC risk (OR =0.62, 95% CI = 0.56 to 0.69). This association was similar according to microsatellite instability, CpG island methylator phenotype and BRAF or KRAS status. However, the association was attenuated for tumors arising through the serrated pathway (OR = 0.81, 95% CI = 0.66 to 1.01) compared with the adenoma-carcinoma pathway (OR = 0.63, 95% CI = 0.55 to 0.73; Phet =.04) and alternate pathway (OR = 0.61, 95% CI = 0.51 to 0.72). Additionally, proximal colon tumors had a weaker association (OR = 0.71, 95% CI = 0.62 to 0.80) compared with rectal (OR = 0.54, 95% CI = 0.46 to 0.63) and distal colon (OR = 0.57, 95% CI = 0.49 to 0.66; Phet =.01) tumors.ConclusionsWe observed a strong inverse association between HT use and overall CRC risk, which may predominantly reflect a benefit of HT use for tumors arising through the adenoma-carcinoma and alternate pathways as well as distal colon and rectal tumors.
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
Mulder, Frits I. , Bosch, Floris T.M. , Young, Annie , Marshall, Andrea , McBane, Robert D. , Carrier, Marc , Kamphuisen, Pieter W. , Bossuyt, Patrick M. , Büller, Harry R. , Es, Nick van , Zemla, Tyler J, McBane, Robert , Carrier, Marc , Zemla, Tyler , Weitz, Jeffrey Ian , Middeldorp, Saskia

Mayo Clinic

Blood | May 12, 2020 | Volume: 136 | Issue: 12 | Pages: 1433-1441

10.1182/blood.2020005819 | PMID 32396939 Get It

Abstract Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWHs) in these patients. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and conference proceedings were searched to identify relevant randomized controlled trials. Additional data were obtained from the original authors to homogenize definitions for all study outcomes. The primary efficacy and safety outcomes were recurrent VTE and major bleeding, respectively. Other outcomes included the composite of recurrent VTE and major bleeding, clinically relevant nonmajor bleeding (CRNMB), and all-cause mortality. Summary relative risks (RRs) were calculated in a random effects meta-analysis. In the primary analysis comprising 2607 patients, the risk of recurrent VTE was nonsignificantly lower with DOACs than with LMWHs (RR, 0.68; 95% CI, 0.39-1.17). Conversely, the risks of major bleeding (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (RR, 1.63; 95% CI, 0.73-3.64) were nonsignificantly higher. The risk of the composite of recurrent VTE or major bleeding was nonsignificantly lower with DOACs than with LMWHs (RR, 0.86; 95% CI, 0.60-1.23). Mortality was comparable in both groups (RR, 0.96; 95% CI, 0.68-1.36). Findings were consistent during the on-treatment period and in those with incidental VTE. In conclusion, DOACs are an effective treatment option for patients with cancer and acute VTE, although caution is needed in patients at high risk of bleeding.